Literature DB >> 8045114

Patients' and caregivers' initial assessments of day-hospital treatment and course of symptoms.

S Priebe1, T Gruyters.   

Abstract

During the first few days after their admission to a day-hospital, 30 patients with schizophrenic or schizoaffective disorders, their clinical case managers, and the therapeutic team in the day-hospital globally assessed the beginning treatment on visual analog scales (VASs). We investigated whether these assessments predicted observer ratings (Brief Psychiatric Rating Scale [BPRS]) and self-ratings of psychopathology during treatment and at discharge. Positive assessments by patients and caregivers were correlated with lower BPRS scores later on in the course of treatment; only the patients' assessments were good predictors of self-rated outcome. Initial global assessments of treatment might indicate qualities of the therapeutic relationship as a relevant nonspecific factor in complex day-hospital treatment.

Entities:  

Mesh:

Year:  1994        PMID: 8045114     DOI: 10.1016/0010-440x(94)90196-1

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  3 in total

1.  Predictors of clinical and social outcomes following involuntary hospital admission: a prospective observational study.

Authors:  Stefan Priebe; Christina Katsakou; Ksenija Yeeles; Tim Amos; Richard Morriss; Duolao Wang; Til Wykes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-22       Impact factor: 5.270

2.  Association of treatment satisfaction and psychopathological sub-syndromes among involuntary patients with psychotic disorders.

Authors:  Michelle Richardson; Christina Katsakou; Stefan Priebe
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-05-22       Impact factor: 4.328

3.  Exploring the initial experience of hospitalisation to an acute psychiatric ward.

Authors:  Agnes Chevalier; Eleni Ntala; Catherine Fung; Stefan Priebe; Victoria J Bird
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.